CDK Inhibitors
CDK inhibitors are a type of cancer treatment that target cyclin-dependent kinases (CDKs), which are enzymes that help regulate the cell cycle—the process by which cells grow and divide. By blocking these enzymes, CDK inhibitors slow down or stop the proliferation of cancer cells, particularly in certain types of breast cancer and other malignancies. This helps to control tumor growth and can enhance the effectiveness of other cancer therapies. Overall, CDK inhibitors represent an important advancement in targeted cancer treatment, improving outcomes for some patients facing specific cancers.
Additional Insights
-
CDK inhibitors are a class of drugs that target cyclin-dependent kinases (CDKs), which are enzymes crucial for cell division and growth. By inhibiting these enzymes, the drugs can slow down or stop the growth of cancer cells, which often divide uncontrollably. These inhibitors are particularly useful in treating certain types of cancers, such as breast and lung cancer, by disrupting the cancer cells' ability to proliferate. This approach helps to slow the disease's progression and can improve patient outcomes when used alongside other treatments.